Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

However, by week 24 (primary end point), the between-treatment difference had decreased and did not reach statistical significance (16.7% [12/72 patients] vs 9.7% [7/72 patients]; Figure 1 ).

also in 111,027 other papers